FDA approves Atezolizumab for Triple-Negative Breast Cancer

The US FDA has granted accelerated approval of a new treatment for triple-negative breast cancer, which is difficult to treat. Further trials are required, but early studies strongly suggest that patients with triple-negative breast cancer benefit from this combination treatment. For further details, click on the link below:




Share This Article

Breast Cancer Ireland

36 Mount Street Upper,
Grand Canal Dock,
Dublin 2, D02 Y982
Republic of Ireland

Email: info@breastcancerireland.com
Tel: 01-533 7570
Charity No: Chy 19926

Breast Cancer Ireland has been incorporated as Breast Cancer Ireland CLG, trading as: Breast Cancer Ireland